Browse the evidence

Use of second generation oral contraceptives (OC) did not significantly improve muscle adaptations to 10 weeks of resistance training compared with nonusers.

Practitioners should note that second generation OCs do not enhance resistance training adaptations in untrained young women.

Current hypertension guidelines do not yet recommend incretin-based therapies as first-line treatment because no large-scale trial has used blood pressure reduction as its primary endpoint, despite robust secondary data showing efficacy.

You cannot currently get GLP-1 medications prescribed specifically for high blood pressure as a first-line treatment under standard insurance guidelines. They are primarily approved for diabetes and weight loss. However, if you have both hypertension and obesity/diabetes, your doctor may prescribe them for those conditions, which will incidentally lower your blood pressure significantly.

Antidiabetic medications can reduce the risk and improve outcomes of cardiovascular diseases.

Consider the cardiovascular benefits when prescribing antidiabetic medications.

The extra amount of protein led to minor changes in body composition but not physical performance or muscle quality.

Practitioners should manage expectations regarding the impact of increased protein on physical performance and muscle quality.

Higher carbohydrate intake is associated with a significant increase in total cardiovascular disease (CVD) events (HR=1.05, 95% CI: 1.00, 1.10).

Practitioners should consider the potential risks of high carbohydrate intake on cardiovascular health.

No significant association was found between dietary carbohydrate and CVD mortality (HR=1.02; 95% CI: 0.91, 1.14).

Dietary carbohydrate intake may not significantly impact CVD mortality, suggesting other factors may be more influential.

Obesity prevalence is projected to grow by 40% in the next decade.

Healthcare practitioners should prepare for increased obesity-related health issues.

FIM programs often prioritize health equity.

Health care providers should ensure that FIM interventions are designed to promote health equity.

New approaches in GLP-1RAs development include multi-agonists and combination therapies.

Practitioners should explore the potential benefits of multi-agonist and combination therapy strategies in GLP-1RA treatments.

Novel GLP-1-based therapeutics are rapidly advancing and may reshape the future landscape of obesity and type 2 diabetes treatment.

Practitioners should consider the potential of these novel agents in treating obesity and type 2 diabetes.

Triple agonists such as retatrutide target GIP, GLP-1, and glucagon receptors to amplify metabolic effects.

Consider the potential of triple agonists in enhancing metabolic outcomes for patients.

The use of mixed methods does not reach acceptable accuracy for 1RM prediction on an individual basis.

Practitioners should be cautious when using mixed methods for individual 1RM predictions.

There are concerns regarding the long-term safety and efficacy of GLP-1 receptor agonists.

Practitioners should monitor patients closely for safety and efficacy when prescribing GLP-1 receptor agonists.

The study of exercise as a preventative or therapeutic treatment is increasingly interdisciplinary and impactful.

Researchers and practitioners should collaborate across disciplines to enhance exercise interventions.

Meta-regression suggested no significant correlation between BP reduction and baseline characteristics such as age, gender, HbA1c, weight, BMI, and percentage of patients with hypertension.

GLP-1 receptor agonists may be effective for BP management regardless of certain baseline characteristics.

Obesity is a disorder of energy metabolism characterized by low usable energy (ATP) in the setting of elevated total energy.

Practitioners should consider the role of energy metabolism in obesity management.

Treatment response heterogeneity is an important area of research in personalized and precision medicine.

Researchers should focus on understanding individual responses to treatments in nutrition and obesity.

Financial incentives, environmental change strategies, and their combination were not significantly more effective than usual care.

Practitioners should consider that these interventions may not provide significant advantages over standard care.

New pharmacological treatments for obstructive sleep apnea (OSA) might be effective.

Practitioners should consider new pharmacological options for treating OSA.

There is a need to develop new cost-effective strategies for OSA management.

Practitioners should consider implementing innovative and cost-effective strategies for managing OSA.

Sustained remission was observed in 15.8 % (n = 19) over three years and in 12.5 % (n = 15) over four years.

Sustained remission can be a realistic goal for patients on a very low carbohydrate diet.

Tirzepatide, a GLP-1/GIP receptor co-agonist, was approved by the FDA for the treatment of T2DM and provides superior HbA1c reductions.

Healthcare providers can utilize tirzepatide as a more effective treatment option for T2DM.

Less than half of obese patients were considering weight loss in the coming month.

Practitioners should address motivation and readiness to change in obese CHD patients.

The safety profile of tirzepatide is consistent across all phase 3 trials.

Practitioners can expect a consistent safety profile when prescribing tirzepatide.